WO2001012167A3 - Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist - Google Patents

Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist Download PDF

Info

Publication number
WO2001012167A3
WO2001012167A3 PCT/GB2000/003118 GB0003118W WO0112167A3 WO 2001012167 A3 WO2001012167 A3 WO 2001012167A3 GB 0003118 W GB0003118 W GB 0003118W WO 0112167 A3 WO0112167 A3 WO 0112167A3
Authority
WO
WIPO (PCT)
Prior art keywords
muscarinic antagonist
benzothiazolone
aminoethyl
pharmaceutical compositions
anticholinergic muscarinic
Prior art date
Application number
PCT/GB2000/003118
Other languages
French (fr)
Other versions
WO2001012167A2 (en
Inventor
Francis Ince
John Dixon
Philip Ronald Holt
Original Assignee
Astrazeneca Uk Ltd
Francis Ince
John Dixon
Philip Ronald Holt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd, Francis Ince, John Dixon, Philip Ronald Holt filed Critical Astrazeneca Uk Ltd
Priority to AU64604/00A priority Critical patent/AU6460400A/en
Publication of WO2001012167A2 publication Critical patent/WO2001012167A2/en
Publication of WO2001012167A3 publication Critical patent/WO2001012167A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition, pharmaceutical product or kit comprising a first active ingredient (A) being 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H)-one or a pharmaceutically acceptable salt thereof, and a second active ingredient (B) being an anticholinergic muscarinic antagonist, for use in the treatment of obstructive airways diseases.
PCT/GB2000/003118 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist WO2001012167A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64604/00A AU6460400A (en) 1999-08-18 2000-08-14 Pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902935A SE9902935D0 (en) 1999-08-18 1999-08-18 Pharmaceutical compositions
SE9902935-7 1999-08-18

Publications (2)

Publication Number Publication Date
WO2001012167A2 WO2001012167A2 (en) 2001-02-22
WO2001012167A3 true WO2001012167A3 (en) 2001-09-20

Family

ID=20416693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003118 WO2001012167A2 (en) 1999-08-18 2000-08-14 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist

Country Status (3)

Country Link
AU (1) AU6460400A (en)
SE (1) SE9902935D0 (en)
WO (1) WO2001012167A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063957A1 (en) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and dopamine agonists
DE10111843A1 (en) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Compounds for the treatment of inflammatory diseases
JP4851937B2 (en) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド Compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702385D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CN102124003A (en) 2008-06-18 2011-07-13 阿斯利康(瑞典)有限公司 Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024473A1 (en) * 1992-05-27 1993-12-09 Fisons Plc 7-(2-aminoethyl)-benzothiazolones

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARNES P.J.: "New therapies for chronic obstructive pulmonary disease.", THORAX, (1998) 53/2 (137-147)., XP000986442 *
CHAPMAN K R: "An international perspective on anticholinergic therapy.", AMERICAN JOURNAL OF MEDICINE, (1996 JAN 29) 100 (1A) 2S-4S. REF: 19, XP000986461 *
IKEDA A. ET AL: "Pharmacological treatment in acute exacerbations of chronic obstructive pulmonary disease.", DRUGS AND AGING, (1998) 12/2 (129-137)., XP000986468 *
LURIE A. ET AL: "Long-term management of reversible obstructive airways disease in adults.", LUNG, (1990) 168/SUPPL. (154-167)., XP000986437 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056100B2 (en) 1999-07-14 2015-06-16 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9333195B2 (en) 1999-07-14 2016-05-10 Almirall, S.A. Quinuclidine derivatives and medicinal compositions containing the same
US9254262B2 (en) 2008-03-13 2016-02-09 Almirall, S.A. Dosage and formulation

Also Published As

Publication number Publication date
SE9902935D0 (en) 1999-08-18
WO2001012167A2 (en) 2001-02-22
AU6460400A (en) 2001-03-13

Similar Documents

Publication Publication Date Title
WO2001012167A3 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and an anticholinergic muscarinic antagonist
CA2229597A1 (en) Oral fast-dissolving compositions for dopamine agonists
HUP0400203A3 (en) Use of combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases, for preparation of pharmaceutical compositions
EE05404B1 (en) A quinuclidine derivative, its preparation and its use in the preparation of a medicament for the treatment of respiratory, urinary or gastrointestinal diseases, and a pharmaceutical composition containing it
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
EG25542A (en) Oral dosge forms for propiverne or pharmaceutically acceptable salts thereof having prolonged release of the active agent
EE04850B1 (en) Use of pyrimidine derivatives for the preparation of a medicament for the treatment of HIV infection, a compound, a pharmaceutical composition containing it, a process for the preparation of a compound and a composition, and a combination preparation for use in the treatment of HIV infection.
IL170120A (en) 1,2,4-triazine compounds, their use for preparation of medicaments for treating or preventing hiv, pharmaceutical compositions comprising the same and processes for their preparation
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
WO2001098290A3 (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
CA2381097A1 (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
WO2003070236A3 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
CA2460865A1 (en) Quinoline derivatives as neuropeptide y antagonists
WO2002078745A3 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
WO2003015779A3 (en) Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole
EP1830191A3 (en) Pharmaceutical preparations containing thiazolidinediones for the treatment of endocrine autoimmune diseases
HUP0400548A3 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
WO2001011933A3 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a pde4 inhibitor
NO20013645L (en) Use of Pyridazino [4,5-b] Indole-1-Acetamide Derivatives for the Preparation of Medicines for the Treatment of Disease-Related Dysfunction of the Peripheral Benzodiazepine Receptors
WO2003077857A3 (en) N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
WO2001012191A3 (en) Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid
WO2001012192A3 (en) Pharmaceutical compositions comprising a-(2-aminoethyl)-benzothiazolone and disodium cromoglycate or nedocromil

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09674084

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP